ECSP056180A - Alquil-estra-1,3,5(10)-trienos 8beta-vinil-11beta-(omega-sustituidos) - Google Patents

Alquil-estra-1,3,5(10)-trienos 8beta-vinil-11beta-(omega-sustituidos)

Info

Publication number
ECSP056180A
ECSP056180A EC2005006180A ECSP056180A ECSP056180A EC SP056180 A ECSP056180 A EC SP056180A EC 2005006180 A EC2005006180 A EC 2005006180A EC SP056180 A ECSP056180 A EC SP056180A EC SP056180 A ECSP056180 A EC SP056180A
Authority
EC
Ecuador
Prior art keywords
estra
triens
vinil
8beta
11beta
Prior art date
Application number
EC2005006180A
Other languages
English (en)
Inventor
Nico Braeuer
Olaf Peters
Rolf Bohlmann
Margit Richter
Hans Peter Muhn
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP056180A publication Critical patent/ECSP056180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a alquil-estra-1,3,5(10)-trienos 8 -vinil-11ß-( -sustituidos) de la fórmula general I con actividad antagonista de ERß, a procedimientos para su preparación, a sus productos intermediarios, a preparados farmacéuticos que contienen los compuestos según la invención, así como a su uso para preparar medicamentos. Los nuevos compuestos pueden aplicarse para la anticoncepción en el hombre y en la mujer, sin que afecten otros órganos sensibles a los estrógenos, tales como el útero o el hígado. También son apropiados para el tratamiento de enfermedades proliferativas benignas o malignas del ovario como carcinomas de ovario y tumores de células granulosas.
EC2005006180A 2003-04-22 2005-11-21 Alquil-estra-1,3,5(10)-trienos 8beta-vinil-11beta-(omega-sustituidos) ECSP056180A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10318896A DE10318896A1 (de) 2003-04-22 2003-04-22 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene

Publications (1)

Publication Number Publication Date
ECSP056180A true ECSP056180A (es) 2006-04-19

Family

ID=33304956

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006180A ECSP056180A (es) 2003-04-22 2005-11-21 Alquil-estra-1,3,5(10)-trienos 8beta-vinil-11beta-(omega-sustituidos)

Country Status (21)

Country Link
US (1) US7375098B2 (es)
EP (1) EP1622924A2 (es)
JP (1) JP2006524202A (es)
KR (1) KR20060005386A (es)
CN (1) CN100381457C (es)
AR (1) AR044056A1 (es)
AU (1) AU2004232462A1 (es)
BR (1) BRPI0409794A (es)
CA (1) CA2522354A1 (es)
CL (1) CL2004000856A1 (es)
CR (1) CR8053A (es)
DE (1) DE10318896A1 (es)
EA (1) EA009606B1 (es)
EC (1) ECSP056180A (es)
MX (1) MXPA05011386A (es)
NO (1) NO20055493L (es)
PE (1) PE20050423A1 (es)
RS (1) RS20050793A (es)
UY (1) UY28284A1 (es)
WO (1) WO2004094451A2 (es)
ZA (1) ZA200509447B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302790T1 (de) * 2000-04-12 2005-09-15 Schering Ag 8beta-substituierte-11beta-pentyl-und 11beta- hexyl-estra-1,3,5(10)-trienderivate
CN101052641A (zh) 2004-09-07 2007-10-10 惠氏公司 6H－[1]苯并吡喃并[4,3－b]喹啉及其作为雌激素药物的用途
KR20070088695A (ko) * 2005-10-05 2007-08-29 시코르, 인크. 풀베스트란트 이성질체의 분리 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1226155E (pt) * 1999-11-02 2007-07-26 Bayer Schering Pharma Ag 18-nor-esteróides como estrogénios selectivamente activos
ATE302790T1 (de) * 2000-04-12 2005-09-15 Schering Ag 8beta-substituierte-11beta-pentyl-und 11beta- hexyl-estra-1,3,5(10)-trienderivate
DE10151114A1 (de) * 2001-10-15 2003-04-17 Schering Ag 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate

Also Published As

Publication number Publication date
UY28284A1 (es) 2004-11-30
RS20050793A (sr) 2008-04-04
US7375098B2 (en) 2008-05-20
EA200501568A1 (ru) 2006-06-30
NO20055493L (no) 2006-01-18
CR8053A (es) 2006-05-29
NO20055493D0 (no) 2005-11-21
JP2006524202A (ja) 2006-10-26
BRPI0409794A (pt) 2006-05-30
US20050065135A1 (en) 2005-03-24
ZA200509447B (en) 2009-08-26
AR044056A1 (es) 2005-08-24
CA2522354A1 (en) 2004-11-04
DE10318896A1 (de) 2004-11-25
CN1777618A (zh) 2006-05-24
KR20060005386A (ko) 2006-01-17
CL2004000856A1 (es) 2005-03-28
CN100381457C (zh) 2008-04-16
WO2004094451A2 (de) 2004-11-04
AU2004232462A1 (en) 2004-11-04
EP1622924A2 (de) 2006-02-08
EA009606B1 (ru) 2008-02-28
MXPA05011386A (es) 2006-04-18
WO2004094451A3 (de) 2004-12-23
PE20050423A1 (es) 2005-08-13

Similar Documents

Publication Publication Date Title
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
BR0113234A (pt) Polimorfos de um análogo de epotilona
UY28271A1 (es) Compuestos químicos
SV2002000357A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo ref pc10748amag/bb
ECSP003713A (es) Derivados de purina
ECSP003712A (es) Derivados de la purina
PA8557501A1 (es) Benzamida, heteroarilamida y amidas inversas
MX9603052A (es) Analogos delta 12.13 iso-taxol uso antineoplastico y las composiciones farmaceuticas que los contienen.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CY1107815T1 (el) 1,3 - διϋποκατεστημεναι και 1,3,3 -τριϋποκατεστημεναι πυρρολιδιναι ως συνδεσμικα μεσα υποδοχεως ισταμινης -3, και θεραπευτικαι εφαρμογαι των
UY28366A1 (es) Compuestos químicos
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
UY27983A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
CU23792A3 (es) Novedosos anticuerpos antiproliferación
UY29875A1 (es) Compuestos quimicos
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
ECSP056180A (es) Alquil-estra-1,3,5(10)-trienos 8beta-vinil-11beta-(omega-sustituidos)